MCID: DCT002
MIFTS: 56

Ductal Carcinoma in Situ

Categories: Cancer diseases

Aliases & Classifications for Ductal Carcinoma in Situ

MalaCards integrated aliases for Ductal Carcinoma in Situ:

Name: Ductal Carcinoma in Situ 12 28 14
Noninfiltrating Intraductal Carcinoma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0060074
UMLS 69 C0007124

Summaries for Ductal Carcinoma in Situ

MalaCards based summary : Ductal Carcinoma in Situ, also known as noninfiltrating intraductal carcinoma, is related to comedo carcinoma and breast reconstruction. An important gene associated with Ductal Carcinoma in Situ is AKT1 (AKT Serine/Threonine Kinase 1), and among its related pathways/superpathways are ERK Signaling and PI3K-Akt signaling pathway. The drugs Nolvadex and Anastrozole have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and testes, and related phenotypes are Increased cell death HMECs cells and cellular

Wikipedia : 72 Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive... more...

Related Diseases for Ductal Carcinoma in Situ

Diseases related to Ductal Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 252)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 32.1 ERBB2 ESR1
2 breast reconstruction 30.9 BRCA1 BRCA2
3 gynecomastia 30.5 AR CYP19A1 ESR1 PGR
4 mammographic density 30.5 CYP19A1 ESR1 PGR
5 papillary carcinoma 30.2 CDH1 ERBB2 MUC1 PGR
6 lobular neoplasia 30.1 BRCA1 CDH1 ERBB2 ESR1 MUC1
7 breast disease 30.1 ERBB2 ESR1 KRT5 PGR TP53
8 bilateral breast cancer 29.9 BRCA1 BRCA2 ERBB2 ESR1 PGR
9 papilloma 29.7 CCND1 KRT14 KRT5 KRT8 TP53
10 breast ductal carcinoma 28.4 AR BRCA1 CCND1 CDH1 EGFR ERBB2
11 squamous cell carcinoma 28.2 CCND1 CDH1 EGFR ERBB2 MUC1 PTGS2
12 breast cancer 25.2 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
13 scirrhous adenocarcinoma 10.6 ERBB2 PGR
14 breast apocrine carcinoma 10.6 ERBB2 PGR
15 endometrium carcinoma in situ 10.6 PGR TP53
16 vulvar syringoma 10.6 ESR1 PGR
17 breast intraductal proliferative lesion 10.6 EGFR ERBB2
18 lung leiomyoma 10.6 ESR1 PGR
19 endometrial clear cell adenocarcinoma 10.6 ESR1 TP53
20 glassy cell carcinoma of the cervix 10.6 ERBB2 ESR1 PGR
21 hereditary site-specific ovarian cancer syndrome 10.6 BRCA1 BRCA2
22 breast papillomatosis 10.6 CCND1 ERBB2
23 vulvar benign neoplasm 10.6 ESR1 PGR
24 brca1 hereditary breast and ovarian cancer syndrome 10.5 BRCA1 BRCA2
25 trigonitis 10.5 ESR1 PGR
26 vestibular gland benign neoplasm 10.5 ESR1 PGR TP53
27 bartholin's gland adenoma 10.5 ESR1 PGR TP53
28 brain ependymoma 10.5 EGFR TP53
29 vulvar leiomyoma 10.5 ESR1 PGR
30 uterine body mixed cancer 10.5 ERBB2 PGR TP53
31 bartholin's gland benign neoplasm 10.5 ESR1 PGR TP53
32 cervical carcinosarcoma 10.5 ESR1 PGR TP53
33 intracystic papillary adenoma 10.5 EGFR ERBB2 PGR
34 progesterone-receptor negative breast cancer 10.5 EGFR ERBB2 PGR
35 adenosarcoma 10.5 ESR1 PGR TP53
36 non-proliferative fibrocystic change of the breast 10.5 CCND1 ERBB2 TP53
37 serous cystadenocarcinoma 10.5 AKT1 PGR TP53
38 papillary serous adenocarcinoma 10.5 BRCA1 PGR TP53
39 tuberculous salpingitis 10.5 BRCA1 BRCA2 ERBB2
40 predominantly cortical thymoma 10.5 ESR1 KRT14 PGR
41 adenomyosis 10.4 ESR1 PGR PTGS2
42 nosophobia 10.4 BRCA1 BRCA2 PGR
43 cancerophobia 10.4 BRCA1 BRCA2 PGR
44 esophagus adenocarcinoma 10.4 ERBB2 PTGS2 TP53
45 barrett's adenocarcinoma 10.4 ERBB2 PTGS2 TP53
46 uterine corpus cancer 10.4 ERBB2 ESR1 PGR TP53
47 dysgerminoma of ovary 10.4 BRCA1 BRCA2 PGR
48 breast mucoepidermoid carcinoma 10.4 MUC1 PGR
49 estrogen excess 10.4 CYP19A1 ESR1 PGR
50 breast osteosarcoma 10.4 ERBB2 KRT8

Graphical network of the top 20 diseases related to Ductal Carcinoma in Situ:



Diseases related to Ductal Carcinoma in Situ

Symptoms & Phenotypes for Ductal Carcinoma in Situ

GenomeRNAi Phenotypes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.1 BRCA1 EGFR PGR PIP S100A7 TP53

MGI Mouse Phenotypes related to Ductal Carcinoma in Situ:

43 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.48 EGFR ERBB2 ESR1 KRT14 PGR PIP
2 digestive/alimentary MP:0005381 10.47 TP53 AR BRCA1 BRCA2 CCND1 CDH1
3 growth/size/body region MP:0005378 10.47 ESR1 KRT14 KRT5 KRT8 PTGS2 TP53
4 cardiovascular system MP:0005385 10.46 PGR PIP PTGS2 TP53 AKT1 AR
5 endocrine/exocrine gland MP:0005379 10.45 KRT14 PGR PIP PTGS2 TP53 AKT1
6 homeostasis/metabolism MP:0005376 10.45 EGFR ERBB2 ESR1 KRT14 KRT8 PGR
7 hematopoietic system MP:0005397 10.43 AKT1 AR BRCA1 BRCA2 CCND1 CLDN7
8 integument MP:0010771 10.43 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
9 immune system MP:0005387 10.41 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
10 behavior/neurological MP:0005386 10.4 ERBB2 ESR1 KRT5 PGR PTGS2 TP53
11 mortality/aging MP:0010768 10.38 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
12 embryo MP:0005380 10.36 AKT1 AR BRCA1 BRCA2 CDH1 EGFR
13 adipose tissue MP:0005375 10.28 AKT1 AR BRCA1 CYP19A1 EGFR ESR1
14 neoplasm MP:0002006 10.25 PTGS2 TP53 AKT1 AR BRCA1 BRCA2
15 normal MP:0002873 10.18 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
16 limbs/digits/tail MP:0005371 10.16 AR BRCA1 BRCA2 EGFR ERBB2 ESR1
17 muscle MP:0005369 10.16 CYP19A1 EGFR ERBB2 ESR1 PGR PTGS2
18 craniofacial MP:0005382 10.14 AR CCND1 EGFR ERBB2 KRT14 KRT5
19 nervous system MP:0003631 10.14 EGFR ERBB2 ESR1 PTGS2 TP53 AKT1
20 liver/biliary system MP:0005370 10.1 AKT1 AR CYP19A1 EGFR ESR1 KRT8
21 reproductive system MP:0005389 10.06 PGR PIP PTGS2 TP53 AKT1 AR
22 renal/urinary system MP:0005367 9.86 AR BRCA1 CLDN7 CYP19A1 EGFR ESR1
23 pigmentation MP:0001186 9.8 AR BRCA1 CYP19A1 EGFR KRT14 TP53
24 respiratory system MP:0005388 9.61 AKT1 BRCA1 CCND1 EGFR ERBB2 ESR1
25 skeleton MP:0005390 9.4 CYP19A1 EGFR ERBB2 ESR1 PGR PTGS2

Drugs & Therapeutics for Ductal Carcinoma in Situ

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Nolvadex 17 45 TAMOXIFEN CITRATE AstraZeneca October 1998

Drugs for Ductal Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 193)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
2
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
3
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
4
Doxorubicin Approved, Investigational Phase 3,Phase 1 23214-92-8 31703
5
Progesterone Approved, Vet_approved Phase 3,Phase 2,Early Phase 1 57-83-0 5994
6
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
7
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
8
Epirubicin Approved Phase 3 56420-45-2 41867
9
Fluorouracil Approved Phase 3 51-21-8 3385
10
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
11
Letrozole Approved, Investigational Phase 3,Phase 2 112809-51-5 3902
12
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1 180288-69-1 9903
13
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
14
Metformin Approved Phase 3 657-24-9 4091 14219
15
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
16
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
17
Pembrolizumab Approved Phase 3,Early Phase 1 1374853-91-4
18
Adenosine Approved, Investigational Phase 3 58-61-7 60961
19
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 77-92-9 311
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
21
leucovorin Approved, Nutraceutical Phase 3 58-05-9 143 6006
22
Doxil Approved June 1999 Phase 3,Phase 1 31703
23
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2 114977-28-5 148124 9877265
24 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
25 Aromatase Inhibitors Phase 3,Phase 2
26 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1
27 Estrogen Antagonists Phase 3,Phase 2,Phase 1
28 Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1
29 Estrogens Phase 3,Phase 2,Phase 1
30 Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
31 Hormones Phase 3,Phase 2,Phase 1,Early Phase 1
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
33 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1
34 Steroid Synthesis Inhibitors Phase 3,Phase 2
35 Anti-Bacterial Agents Phase 3,Phase 1
36 Antibiotics, Antitubercular Phase 3,Phase 1
37 Topoisomerase Inhibitors Phase 3,Phase 1
38 Anti-Allergic Agents Phase 3
39 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2
40 Dermatologic Agents Phase 3
41 mometasone furoate Phase 3
42 Contraceptive Agents Phase 3,Early Phase 1
43 Contraceptive Agents, Male Phase 3
44 Contraceptives, Oral Phase 3,Early Phase 1
45 Estrogens, Conjugated (USP) Phase 3,Phase 2
46
Medroxyprogesterone Phase 3 520-85-4 10631
47 Alkylating Agents Phase 3
48 Antimetabolites Phase 3,Phase 2,Phase 1
49 Antimetabolites, Antineoplastic Phase 3
50 Antimitotic Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 206)

# Name Status NCT ID Phase Drugs
1 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
2 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
3 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator Unknown status NCT00321048 Phase 3
4 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
5 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
6 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3 mometasone furoate
7 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
8 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
9 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
10 Study of Docetaxel in Breast Cancer Patients Completed NCT00174707 Phase 3 epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, cyclophosphamide
11 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
12 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women Completed NCT00003906 Phase 3 Raloxifene;Tamoxifen
13 Management of Low-risk DCIS Recruiting NCT02492607 Phase 3
14 Oxybutynin Chloride in Managing Hot Flashes Recruiting NCT02961790 Phase 3 Oxybutynin Chloride
15 Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer Recruiting NCT01905046 Phase 3 metformin hydrochloride
16 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
17 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Recruiting NCT03036488 Phase 3 Carboplatin;Paclitaxel;Doxorubicin;Epirubicin;Cyclophosphamide;Placebo
18 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
19 Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS) Active, not recruiting NCT00907868 Phase 3
20 Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
21 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ Active, not recruiting NCT00072462 Phase 3 tamoxifen citrate;Anastrozole
22 Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
23 APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer Active, not recruiting NCT00402519 Phase 3
24 RAPID: Randomized Trial of Accelerated Partial Breast Irradiation Active, not recruiting NCT00282035 Phase 3
25 Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer Active, not recruiting NCT00878709 Phase 3 neratinib
26 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
27 A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) Active, not recruiting NCT01772472 Phase 3 trastuzumab;trastuzumab emtansine
28 Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS Withdrawn NCT00324714 Phase 3 risedronate sodium
29 Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) Unknown status NCT00669747 Phase 2 Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
30 Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
31 Dose Optimization for Pulsed-dose-rate (PDR)/High-dose-rate (HDR) Brachytherapy Alone for Early Breast Cancer Unknown status NCT01175694 Phase 2
32 Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland Unknown status NCT01630226 Phase 2 Neoadjuvant Cisplatin Chemotherapy
33 Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors Unknown status NCT02150525 Phase 2
34 Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
35 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
36 Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer Completed NCT00416403 Phase 2 fluvastatin sodium
37 Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) Completed NCT01023477 Phase 1, Phase 2 Chloroquine Standard Dose (500mg/week);Chloroquine Low Dose (250mg/week)
38 Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer Completed NCT00054301 Phase 2
39 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast Completed NCT03002766 Phase 2
40 MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ Completed NCT00586326 Phase 2
41 Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy Completed NCT00843167 Phase 2
42 Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer Completed NCT00354640 Phase 2 anastrozole;simvastatin
43 Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen Completed NCT00764322 Phase 2 tamoxifen citrate
44 Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer Completed NCT00334542 Phase 2 simvastatin
45 Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer Completed NCT00244959 Phase 2 anastrozole
46 Letrozole in Preventing Breast Cancer in Postmenopausal Women Completed NCT00090857 Phase 2 Letrozole
47 Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms Completed NCT01194440 Phase 2 letrozole;zoledronic acid
48 A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer. Completed NCT00545688 Phase 2 Herceptin;Docetaxel;Pertuzumab
49 Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease Completed NCT00031720 Phase 2 Tamoxifen
50 Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing Surgery Recruiting NCT02694809 Phase 2 Conjugated Estrogens/Bazedoxifene

Search NIH Clinical Center for Ductal Carcinoma in Situ

Genetic Tests for Ductal Carcinoma in Situ

Genetic tests related to Ductal Carcinoma in Situ:

# Genetic test Affiliating Genes
1 Ductal Carcinoma in Situ 28

Anatomical Context for Ductal Carcinoma in Situ

MalaCards organs/tissues related to Ductal Carcinoma in Situ:

38
Breast, Lymph Node, Testes, Bone, Skin, Prostate, Liver

Publications for Ductal Carcinoma in Situ

Articles related to Ductal Carcinoma in Situ:

(show top 50) (show all 872)
# Title Authors Year
1
Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. ( 29394917 )
2018
2
Prediction of Occult Invasive Disease in Ductal Carcinoma in Situ Using Deep Learning Features. ( 29398498 )
2018
3
Trends and clinicopathological predictors of axillary evaluation in ductal carcinoma in situ patients treated with breast-conserving therapy. ( 29271113 )
2018
4
Hypofractionated volumetric modulated arc therapy in ductal carcinoma in situ: toxicity and cosmetic outcome from a prospective series. ( 29322827 )
2018
5
Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ. ( 29439886 )
2018
6
A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis. ( 29445939 )
2018
7
Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database. ( 29383628 )
2018
8
The association between post-diagnosis health behaviors and long-term quality of life in survivors of ductal carcinoma in situ: a population-based longitudinal cohort study. ( 29417425 )
2018
9
Controversies Regarding the Diagnosis and Management of Ductal Carcinoma In Situ. ( 29428007 )
2018
10
Role of Preoperative Variables in Reducing the Rate of Occult Invasive Disease for Women Considering Active Surveillance for Ductal Carcinoma In Situ. ( 29344621 )
2018
11
Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. ( 29398324 )
2018
12
The PPARI^ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ. ( 29350308 )
2018
13
Role of Preoperative Variables in Reducing the Rate of Occult Invasive Disease for Women Considering Active Surveillance for Ductal Carcinoma In Situ-Reply. ( 29344613 )
2018
14
Recurrence outcomes after omission of postoperative radiotherapy following breast-conserving surgery for ductal carcinoma in situ of the breast: a multicenter, retrospective study in Korea (KROG 16-02). ( 28083820 )
2017
15
Ductal Carcinoma in situ Detected during Prospective MR Imaging Screening of a Woman with a BRCA2 Mutation: The First Case Report in Japan. ( 28090007 )
2017
16
Point: Should Radiation Therapy After Surgery for Ductal Carcinoma In Situ Be Standard Practice? ( 28812305 )
2017
17
Association Between Hospital Financial Distress and Immediate Breast Reconstruction Surgery After Mastectomy Among Women With Ductal Carcinoma In Situ. ( 29214316 )
2017
18
Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma in situ. ( 27871025 )
2017
19
Patient-reported outcomes in ductal carcinoma in situ: A systematic review. ( 27987454 )
2017
20
Adjuvant radiotherapy versus observation following lumpectomy in ductal carcinoma in-situ: A meta-analysis of randomized controlled trials. ( 28833776 )
2017
21
Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features. ( 28611201 )
2017
22
Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women. ( 29207971 )
2017
23
Margin width and local recurrence after breast conserving surgery for ductal carcinoma in situ. ( 28917445 )
2017
24
Severe depression more common in patients with ductal carcinoma in situ than early-stage invasive breast cancer patients. ( 28894982 )
2017
25
Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis. ( 28394473 )
2017
26
Ductal Carcinoma in Situ: Quantitative Preoperative Breast MR Imaging Features Associated with Recurrence after Treatment. ( 28914599 )
2017
27
Risk of death from breast cancer after treatment for ductal carcinoma in situ. ( 28832961 )
2017
28
A Potential Additional Variable to Consider in the Surgical Treatment of Ductal Carcinoma in Situ. ( 29230119 )
2017
29
Outcomes for Women with Minimal-Volume Ductal Carcinoma In Situ Completely Excised at Core Biopsy. ( 28828599 )
2017
30
miRNAs as Biomarkers for Predicting the Progression of Ductal Carcinoma in Situ. ( 29246496 )
2017
31
Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma In Situ of Breast. ( 28894698 )
2017
32
Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ. ( 28885232 )
2017
33
Management of breast ductal carcinoma in situ in Catalonia, Spain: Results from the Grup Oncologic CalalA -OccitA -Catalonia survey with 9-year follow up. ( 28806663 )
2017
34
Trends in cardiac mortality in women with ductal carcinoma in situ. ( 27858317 )
2017
35
Breast ductal carcinoma in situ in an unscreened population: presentation, diagnosis and management at a single tertiary centre. ( 28876551 )
2017
36
Identifying progression predictors of breast ductal carcinoma in situ. ( 27864452 )
2017
37
Radiation Therapy Following Breast Conserving Surgery for Ductal Carcinoma in situ: Yes or No? ( 28862116 )
2017
38
Health-related behaviors and mortality outcomes in women diagnosed with ductal carcinoma in situ. ( 28058695 )
2017
39
Impact of Detection Method and Accompanying Ductal Carcinoma in Situ on Prognosis of T1a,bN0 Breast Cancer. ( 28819437 )
2017
40
Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. ( 28326600 )
2017
41
Counterpoint: Should Radiation Therapy After Surgery for Ductal Carcinoma In Situ Be Standard Practice? ( 28831777 )
2017
42
Clinicopathological Features of Ductal Carcinoma In Situ from (18)F-FDG-PET Findings. ( 28870933 )
2017
43
Ki-67 Expression as a Factor Predicting Recurrence of Ductal Carcinoma In Situ of the Breast: A Systematic Review and Meta-Analysis. ( 29325859 )
2017
44
Variable Appearances of Ductal Carcinoma In Situ Calcifications on Digital Mammography, Synthesized Mammography, and Tomosynthesis: A Pictorial Essay. ( 28947267 )
2017
45
Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma in situ through activation of TGFI^ signaling. ( 28512126 )
2017
46
(18)F-fluorodeoxyglucose uptake as predictor for invasion in preoperatively diagnosed breast ductal carcinoma in situ: Significance in cases without mass formation. ( 28781782 )
2017
47
The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study. ( 29096155 )
2017
48
Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. ( 28338653 )
2017
49
Effect of radiotherapy after breast-conserving surgery in older patients with early breast cancer and breast ductal carcinoma in situ: a meta-analysis. ( 28415667 )
2017
50
Synchronous Ductal Carcinoma In Situ and Intravascular Large B-cell Lymphoma of the Breast. ( 28582274 )
2017

Variations for Ductal Carcinoma in Situ

Cosmic variations for Ductal Carcinoma in Situ:

9 (show all 36)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10656 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 7
2 COSM10660 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>A p.R273H 7
3 COSM43814 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.587G>C p.R196P 7
4 COSM11089 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.584T>C p.I195T 7
5 COSM43559 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.517G>T p.V173L 7
6 COSM10662 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.743G>A p.R248Q 7
7 COSM10701 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.824G>T p.C275F 7
8 COSM10867 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.797G>A p.G266E 7
9 COSM44415 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.711G>C p.M237I 7
10 COSM44737 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.860A>G p.E287G 7
11 COSM6932 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.733G>A p.G245S 7
12 COSM10779 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>T p.R273L 7
13 COSM43714 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.836G>A p.G279E 7
14 COSM44901 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.532C>G p.H178D 7
15 COSM12458 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1634A>C p.E545A 7
16 COSM760 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1624G>A p.E542K 7
17 COSM763 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1633G>A p.E545K 7
18 COSM775 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3140A>G p.H1047R 7
19 COSM754 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1035T>A p.N345K 7
20 COSM776 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3140A>T p.H1047L 7
21 COSM774 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3139C>T p.H1047Y 7
22 COSM580 NRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.181C>A p.Q61K 7
23 COSM565 NRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>C p.G12A 7
24 COSM6057047 NOTCH1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.7372C>T p.P2458S 7
25 COSM6005481 MAP2K2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.931G>T p.D311Y 7
26 COSM521 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>A p.G12D 7
27 COSM516 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.34G>T p.G12C 7
28 COSM532 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.38G>A p.G13D 7
29 COSM520 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>T p.G12V 7
30 COSM4595028 KMT2C breast,NS,carcinoma in situ,ductal carcinoma in situ c.2681G>A p.R894Q 7
31 COSM1179671 KMT2C breast,NS,carcinoma in situ,ductal carcinoma in situ c.925C>T p.P309S 7
32 COSM6057048 HRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.148A>G p.T50A 7
33 COSM14060 ERBB2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2264T>C p.L755S 7
34 COSM19786 CDH1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.779C>T p.P260L 7
35 COSM6057049 AKT1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.61A>G p.T21A 7
36 COSM33765 AKT1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.49G>A p.E17K 7

Expression for Ductal Carcinoma in Situ

Search GEO for disease gene expression data for Ductal Carcinoma in Situ.

Pathways for Ductal Carcinoma in Situ

Pathways related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 AKT1 BRCA1 CCND1 CDH1 EGFR ERBB2
2
Show member pathways
13.02 AKT1 BRCA1 CCND1 EGFR PTGS2 TP53
3
Show member pathways
12.97 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
4
Show member pathways
12.75 AKT1 CDH1 ERBB2 ESR1 PTGS2 TP53
5
Show member pathways
12.72 BRCA1 BRCA2 CCND1 ESR1 TP53
6
Show member pathways
12.59 AKT1 CCND1 EGFR ERBB2 ESR1 TP53
7 12.58 AKT1 AR BRCA2 CCND1 CDH1 EGFR
8
Show member pathways
12.53 AKT1 CCND1 EGFR ERBB2 TP53
9 12.52 BRCA1 CCND1 EGFR ERBB2 PTGS2 TP53
10
Show member pathways
12.5 AKT1 CDH1 EGFR ERBB2 MUC1 TP53
11 12.47 AKT1 CCND1 CDH1 PTGS2 TP53
12
Show member pathways
12.42 AKT1 BRCA1 ESR1 PTGS2
13
Show member pathways
12.32 AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
14
Show member pathways
12.31 AKT1 CCND1 EGFR ERBB2 ESR1 PTGS2
15
Show member pathways
12.29 AKT1 BRCA1 CCND1 TP53
16
Show member pathways
12.27 AKT1 CCND1 EGFR ERBB2 TP53
17
Show member pathways
12.26 BRCA1 CCND1 ESR1 PGR
18 12.26 AKT1 CCND1 EGFR ERBB2 ESR1 TP53
19
Show member pathways
12.12 AKT1 CCND1 EGFR ERBB2
20
Show member pathways
12.12 AKT1 AR CCND1 EGFR ERBB2
21 12.11 AKT1 CLDN7 EGFR TP53
22
Show member pathways
12.08 AKT1 EGFR ERBB2 TP53
23 12.06 CCND1 EGFR PTGS2 TP53
24 12.06 AKT1 CCND1 CDH1 EGFR PTGS2 TP53
25 12.03 AKT1 CCND1 ESR1 TP53
26 12.02 AKT1 CCND1 ERBB2 TP53
27 12 AKT1 CCND1 EGFR TP53
28 12 AKT1 CCND1 MUC1 PTGS2 TP53
29
Show member pathways
11.98 EGFR ERBB2 ESR1 PGR
30
Show member pathways
11.98 AKT1 BRCA2 CCND1 EGFR ERBB2 TP53
31 11.91 AKT1 CCND1 PTGS2 TP53
32 11.84 AKT1 KRT14 KRT5 TP53
33
Show member pathways
11.83 BRCA1 BRCA2 TP53
34 11.81 AKT1 AR BRCA1 CCND1 EGFR
35 11.8 AR CCND1 CDH1
36 11.79 AKT1 AR ESR1
37 11.78 AKT1 BRCA1 ERBB2 TP53
38 11.76 CDH1 EGFR ERBB2
39
Show member pathways
11.75 CCND1 EGFR ESR1
40 11.73 AKT1 EGFR ERBB2
41 11.73 AKT1 BRCA1 ERBB2 TP53
42 11.73 AKT1 CCND1 EGFR ESR1
43 11.71 AKT1 EGFR ERBB2 TP53
44 11.67 BRCA1 CCND1 ERBB2 S100A7
45 11.67 CCND1 CDH1 EGFR ERBB2 TP53
46
Show member pathways
11.66 AKT1 CCND1 EGFR ERBB2
47 11.63 AKT1 AR BRCA1 CCND1
48 11.62 AKT1 CCND1 TP53
49 11.6 CCND1 EGFR TP53
50 11.57 EGFR ESR1 PTGS2

GO Terms for Ductal Carcinoma in Situ

Cellular components related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.89 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
2 nuclear chromatin GO:0000790 9.56 AR ESR1 MUC1 TP53
3 protein complex GO:0043234 9.23 AKT1 AR BRCA1 BRCA2 EGFR ESR1
4 nucleus GO:0005634 10.09 AKT1 AR BRCA1 BRCA2 CCND1 EGFR

Biological processes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 transcription initiation from RNA polymerase II promoter GO:0006367 9.92 AR CCND1 ESR1 PGR
2 aging GO:0007568 9.91 AKT1 KRT14 PTGS2 TP53
3 positive regulation of protein phosphorylation GO:0001934 9.91 AKT1 CCND1 EGFR ERBB2
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.86 AKT1 EGFR PTGS2
5 response to oxidative stress GO:0006979 9.86 AKT1 EGFR PTGS2 TP53
6 positive regulation of cell growth GO:0030307 9.85 AKT1 EGFR ERBB2
7 response to organic cyclic compound GO:0014070 9.85 CCND1 EGFR PTGS2 TP53
8 cellular response to mechanical stimulus GO:0071260 9.84 AKT1 EGFR PTGS2
9 response to estrogen GO:0043627 9.83 BRCA1 CCND1 ESR1
10 steroid hormone mediated signaling pathway GO:0043401 9.82 AR ESR1 PGR
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.81 AKT1 EGFR PTGS2
12 cellular response to growth factor stimulus GO:0071363 9.8 AKT1 EGFR ERBB2
13 cell proliferation GO:0008283 9.8 AKT1 AR BRCA2 EGFR ERBB2 TP53
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.77 AKT1 EGFR PTGS2
15 cellular response to epidermal growth factor stimulus GO:0071364 9.76 AKT1 EGFR ERBB2
16 epidermis development GO:0008544 9.76 EGFR KRT14 KRT5 S100A7
17 positive regulation of transcription, DNA-templated GO:0045893 9.76 AKT1 AR BRCA1 BRCA2 CDH1 EGFR
18 response to estradiol GO:0032355 9.73 CCND1 EGFR ESR1 PTGS2
19 response to organonitrogen compound GO:0010243 9.71 CCND1 PTGS2 TP53
20 response to organic substance GO:0010033 9.71 AKT1 CCND1 CDH1 PTGS2
21 cellular response to reactive oxygen species GO:0034614 9.69 AKT1 EGFR TP53
22 Leydig cell differentiation GO:0033327 9.68 AR CCND1
23 positive regulation of transcription by RNA polymerase III GO:0045945 9.67 AR ERBB2
24 hemidesmosome assembly GO:0031581 9.67 KRT14 KRT5
25 mitotic G1 DNA damage checkpoint GO:0031571 9.66 CCND1 TP53
26 prostate gland growth GO:0060736 9.65 AR CYP19A1
27 positive regulation of vasoconstriction GO:0045907 9.65 AKT1 EGFR PTGS2
28 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.63 AKT1 EGFR
29 cellular response to indole-3-methanol GO:0071681 9.6 BRCA1 CDH1
30 morphogenesis of an epithelial fold GO:0060571 9.58 AR EGFR
31 chordate embryonic development GO:0043009 9.57 BRCA1 BRCA2
32 response to X-ray GO:0010165 9.54 BRCA2 CCND1 TP53
33 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.49 AR PGR
34 mammary gland alveolus development GO:0060749 9.43 AR CCND1 ESR1
35 response to UV-A GO:0070141 9.13 AKT1 CCND1 EGFR
36 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.92 BRCA1 BRCA2 MUC1 TP53
37 positive regulation of transcription by RNA polymerase II GO:0045944 10.19 AKT1 AR BRCA1 EGFR ESR1 PGR
38 cellular response to DNA damage stimulus GO:0006974 10.06 AKT1 BRCA1 BRCA2 CCND1 TP53
39 positive regulation of gene expression GO:0010628 10.03 AR BRCA1 ERBB2 PIP TP53
40 positive regulation of cell proliferation GO:0008284 10 AKT1 AR CCND1 CLDN7 EGFR PTGS2

Molecular functions related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.99 AR BRCA1 ESR1 PGR S100A7 TP53
2 protein kinase binding GO:0019901 9.83 AKT1 CCND1 EGFR ESR1 TP53
3 identical protein binding GO:0042802 9.81 AKT1 BRCA2 CDH1 CLDN7 EGFR ERBB2
4 beta-catenin binding GO:0008013 9.7 AR CDH1 ESR1
5 ATPase binding GO:0051117 9.67 AR ESR1 PGR
6 protein phosphatase binding GO:0019903 9.65 EGFR ERBB2 TP53
7 steroid hormone receptor activity GO:0003707 9.58 AR ESR1 PGR
8 nuclear receptor activity GO:0004879 9.54 AR ESR1 PGR
9 steroid binding GO:0005496 9.5 AR ESR1 PGR
10 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.46 EGFR ERBB2
11 enzyme binding GO:0019899 9.28 AKT1 AR BRCA1 CCND1 EGFR ESR1
12 nitric-oxide synthase regulator activity GO:0030235 9.13 AKT1 EGFR ESR1
13 protein binding GO:0005515 10.23 AKT1 AR BRCA1 BRCA2 CCND1 CDH1

Sources for Ductal Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....